



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Submission of trial results and layperson summary

SME and academia Clinical Trials Information System (CTIS) two-part
training webinar

Presented by Andrea Seidel-Glätzer on 04 March 2021

Head of Project Management, Coordination Centre for clinical Trials at the University Hospital
Heidelberg

An agency of the European Union





NEWS · 13 SEPTEMBER 2018

Europe's academics fail to report results for 90% of clinical trials

But nearly 70% of industry-sponsored trials report their results within a year of ending


FAILING TO COMPLY

Around half of all clinical trials in the European Union do not report results within a year of ending. Company-sponsored trials are more likely to report within the EU-stipulated one-year deadline than are academic institutions.





- Academia in Europe is struggling with reporting obligations
- Reporting on **national and european** level
- Lack of awareness on reporting obligations
- Reporting in different portals
- **Full data** set needed



- **one single portal**
- Upload of report according to the **specifications in Annex IV**
- **Layperson** summary according to the **specifications in Annex V**
- **Intermediate or final results**

Article 37

End of a clinical trial, temporary halt and early termination of a clinical trial and submission of the results

4. Irrespective of the outcome of a clinical trial, within one year from the end of a clinical trial in all Member States concerned, the sponsor shall submit to the EU database a summary of the results of the clinical trial. The content of that summary is set out in Annex IV.

It shall be accompanied by a summary written in a manner that is understandable to laypersons. The content of that summary is set out in Annex V.

27.5.2014

EN

Official Journal of the European Union

L 158/71

NEW!

ANNEX V

NEW!


CONTENT OF THE SUMMARY OF THE RESULTS OF THE CLINICAL TRIAL FOR LAYPERSONS

The summary of the results of the clinical trial for laypersons shall contain information on the following elements:

1. Clinical trial identification (including title of the trial, protocol number, EU trial number and other identifiers);
2. Name and contact details of the sponsor;
3. General information about the clinical trial (including where and when the trial was conducted, the main objectives of the trial and an explanation of the reasons for conducting it);
4. Population of subjects (including information on the number of subjects included in the trial in the Member State concerned, in the Union and in third countries; age group breakdown and gender breakdown; inclusion and exclusion criteria);
5. Investigational medicinal products used;
6. Description of adverse reactions and their frequency;
7. Overall results of the clinical trial;
8. Comments on the outcome of the clinical trial;
9. Indication if follow up clinical trials are foreseen;
10. Indication where additional information could be found

Recommendations of the expert group on clinical trials for the implementation of Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use



- **Inform** research participants about the trial they participated in
- Patient Engagement-Patient **as partners** in research
- help to **identify clinical trials** easily and evaluate relevance for patient treatment
- Public interest/**Transparency** on trial results
- **Compliance** with the new EU CTR 536/2014



SUMMARY OF RESULTS

LAY PERSON SUMMARY OF RESULTS

CLINICAL STUDY REPORTS






Summary of results

Title *:

Version type *:

Intermediate

Intermediate data analysis date *:



Related document(s) *:

upload

Add document

CLOSE **SAVE** **SUBMIT**

```
graph TD; A[upload] --> B[Add document]; B --> C[SUBMIT];
```




Any questions?

Further information

CT.Sponsortraining@ema.europa.eu

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

Telephone +31 (0)88 781 6000

Send us a question Go to www.ema.europa.eu/contact

Follow us on  **@EMA_News**